Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection.
Sherman, Kenneth E. M.D., Ph.D.; Flamm, Steven L. M.D.; Afdhal, Nezam H. M.D.; Nelson, David R. M.D.; Sulkowski, Mark S. M.D.; Everson, Gregory T. M.D.; Fried, Michael W. M.D.; Adler, Michael M.D., Ph.D.; Reesink, Hendrik W. M.D., Ph.D.; Martin, Marie Ph.D.; Sankoh, Abdul J. Ph.D.; Adda, Nathalie M.D.; Kauffman, Robert S. M.D., Ph.D.; George, Shelley M.D.; Wright, Christopher I. M.D., Ph.D.; Poordad, Fred M.D.; the ILLUMINATE Study Team *
[Article]
New England Journal of Medicine.
365(11):1014-1024, September 15, 2011.
(Format: HTML, PDF)
Background: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations.
Methods: We enrolled patients with chronic infection with HCV genotype 1 who had not previously received treatment. All patients received telaprevir at a dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 [mu]g per week, and ribavirin at a dose of 1000 to 1200 mg per day, for 12 weeks (T12PR12), followed by peginterferon-ribavirin. Patients who had an extended rapid virologic response (undetectable HCV RNA levels at weeks 4 and 12) were randomly assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks (T12PR48). Patients without an extended rapid virologic response were assigned to T12PR48.
Results: Of the 540 patients, a total of 352 (65%) had an extended rapid virologic response. The overall rate of sustained virologic response was 72%. Among the 322 patients with an extended rapid virologic response who were randomly assigned to a study group, 149 (92%) in the T12PR24 group and 140 (88%) in the T12PR48 group had a sustained virologic response (absolute difference, 4 percentage points; 95% confidence interval, -2 to 11), establishing noninferiority. Adverse events included rash (in 37% of patients, severe in 5%) and anemia (in 39%, severe in 6%). Discontinuation of all the study drugs was based on adverse events in 18% of patients overall, as well as in 1% of patients (all of whom were randomly assigned) in the T12PR24 group and 12% of the patients randomly assigned to the T12PR48 group (P<0.001).
Conclusions: In this study, among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in nearly two thirds of patients. (Funded by Vertex Pharmaceuticals and Tibotec; ILLUMINATE ClinicalTrials.gov number, NCT00758043.)
Copyright (C) 2011 Massachusetts Medical Society. All rights reserved.